SCHEMBL23757486

SCHEMBL23757486

C=CCCCOc1ccc(N)c(C(=O)OC)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 3/20 0.50
MAPT P10636 3/20 0.50
HPGD P15428 3/20 0.50
GAA P10253 2/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
CFTR P13569 1/20 0.42
MAOB P27338 4/20 0.40
MAOA P21397 2/20 0.40
GLA P06280 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
GCK P35557 1/20 0.39
ABL1 P00519 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23758029 0.93 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL23757550 0.90 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL23756873 0.86 ALDH1A1 (0.48) ALDH1A1HSD17B10HPGDL3MBTL1GCK
SCHEMBL4257305 0.85 ALDH1A1 (0.56) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL13163934 0.83 ALDH1A1 (0.55) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL1012515 0.83 KDM4E (0.55) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL23757924 0.83 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL7452382 0.82 KDM4E (0.56) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL267612 0.82 ALDH1A1 (0.56) ALDH1A1KDM4EHSD17B10MAPTHPGD
SCHEMBL13740239 0.82 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594277-B2 Macrocyclic ULK1/2 inhibitors SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2026-04-07 US disclosed
US-20230099804-A1 MACROCYCLIC ULK1/2 INHIBITORS Sanford Burnham Prebys Medical Discovery Institute 2023-03-30 US disclosed
CN-115515588-A Macrocyclic ULK1/2 inhibitors 萨克生物研究学院 2022-12-23 CN disclosed
EP-4103183-A1 MACROCYCLIC ULK1/2 INHIBITORS Salk Institute for Biological Studies (US) 2022-12-21 EP disclosed
WO-2021163627-A1 MACROCYCLIC ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12594277-B2 Macrocyclic ULK1/2 inhibitors ULK1, ULK2, ULK3 ALDH1A1 4428/4885KDM4E 2260/4885HSD17B10 2971/4885
US-20230099804-A1 MACROCYCLIC ULK1/2 INHIBITORS ULK1, ULK2, ULK3 ALDH1A1 4090/4885KDM4E 2324/4885HSD17B10 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.